{
    "clinical_study": {
        "@rank": "142999", 
        "acronym": "XARA", 
        "arm_group": [
            {
                "arm_group_label": "8 Units per kg body weight incobotulinumtoxinA (Xeomin)", 
                "arm_group_type": "Experimental", 
                "description": "8 Units per kg body weight (maximum of 200 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 300 Units per injection cycle. Overall maximum dose per injection cycle: 500 Units."
            }, 
            {
                "arm_group_label": "6 Units per kg body weight incobotulinumtoxinA (Xeomin)", 
                "arm_group_type": "Experimental", 
                "description": "6 Units per kg body weight (maximum of 150 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 225 Units per injection cycle. Overall maximum dose per injection cycle: 375 Units."
            }, 
            {
                "arm_group_label": "2 Units per kg body weight incobotulinumtoxinA (Xeomin)", 
                "arm_group_type": "Experimental", 
                "description": "2 Units per kg body weight (maximum of 50 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 75 Units per injection cycle. Overall maximum dose per injection cycle: 125 Units."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether injections of Botulinum toxin type A into\n      muscles of one or both arms alone or in combination with injections into one or both legs\n      are effective and safe in treating children/adolescents (age 2-17 years) with increased\n      muscle tension/uncontrollable muscle stiffness (spasticity) due to cerebral palsy."
        }, 
        "brief_title": "Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy", 
        "completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cerebral Palsy", 
            "Spasticity"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cerebral Palsy", 
                "Muscle Spasticity", 
                "Paralysis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female or male subject of 2 to 17 years of age (inclusive).\n\n          -  Uni- or bilateral Cerebral Palsy (CP) with clinical need for injections with NT 201\n             for the treatment of upper limb (UL) spasticity at least unilaterally.\n\n          -  Ashworth Scale (AS) score in the main clinical target patterns in this study:\n\n               1. Flexed elbow: AS\u22652 in elbow flexors (at least unilaterally). and/or\n\n               2. Flexed Wrist: AS\u22652 in wrist flexors (at least unilaterally).\n\n          -  Clinical need according to the judgment of the investigator in one out of five\n             treatment combinations (A-E, as shown below). AS score must be \u22652 for each target\n             pattern chosen for injection at the Baseline Injection Visit V2.\n\n        A. UL(s) treatment only (GMFCS I-V):\n\n        A1) Unilateral treatment of UL spasticity with 8 U/kg BW NT 201 (maximum of 200 U) for:\n\n          1. At least one of the main clinical target patterns flexed elbow (4 U/kg BW) and/or\n             flexed wrist (2 U/kg BW).\n\n             and\n\n          2. Additional clinical patterns in the same limb (i.e., clenched fist, thumb in palm,\n             and/or pronated forearm) with the remaining units until maximum dose of 8 U/kg BW\n             (maximum of 200 U) for treatment of a single UL is reached.\n\n        or\n\n        A2) Bilateral treatment of UL spasticity with equal doses of 8 U/kg BW NT 201 (maximum of\n        200 U) to each UL. Dose per UL must be distributed between:\n\n          1. At least one of the main clinical target patterns flexed elbow (4 U/kg BW) and/or\n             flexed wrist (2 U/kg BW).\n\n             and\n\n          2. Additional clinical patterns in the same limb (i.e., clenched fist, thumb in palm,\n             and/or pronated forearm) with the remaining units until maximum dose of 8 U/kg BW\n             (maximum of 200 U) for treatment of a single UL is reached.\n\n        B. Unilateral UL and unilateral lower limb (LL) treatment (GMFCS I-V):\n\n        B1) Unilateral treatment of UL spasticity with 8 U/kg BW NT 201 (maximum of 200 U) for:\n\n          1. At least one of the main clinical target patterns flexed elbow (4 U/kg BW) and/or\n             flexed wrist (2 U/kg BW).\n\n             and\n\n          2. Additional clinical patterns in the same limb (i.e., clenched fist, thumb in palm,\n             and/or pronated forearm) with the remaining units until maximum dose of 8 U/kg BW\n             (maximum of 200 U) for treatment of a single UL is reached.\n\n        plus\n\n        B2) Ipsilateral unilateral treatment of LL spasticity with 8 U/kg BW NT 201 (maximum of\n        200 U). Dose to LL must be distributed to at least one of clinical target patterns pes\n        equinus, flexed knee, adducted thigh, and extended great toe as clinically needed.\n\n        C. Unilateral UL and bilateral LL treatment (GMFCS I-III)\n\n        C1) Unilateral treatment of UL spasticity with 8 U/kg BW NT 201 (maximum of 200 U) for:\n\n          1. At least one of the main clinical target patterns flexed elbow (4 U/kg BW) and/or\n             flexed wrist (2 U/kg BW).\n\n             and\n\n          2. Additional clinical patterns in the same limb (i.e., clenched fist, thumb in palm,\n             and/or pronated forearm) with the remaining units until maximum dose of 8 U/kg BW\n             (maximum of 200 U) for treatment of a single UL is reached.\n\n        plus\n\n        C2) Bilateral treatment of LL spasticity with 12 U/kg BW (maximum of 300 U). Dose must be\n        distributed into at least one of clinical target patterns pes equinus, flexed knee,\n        adducted thigh, and extended great toe, on each side. Dose distribution may vary between\n        sides as clinically needed.\n\n        D. Unilateral UL and bilateral LL treatment (GMFCS IV and V)\n\n        D1) Unilateral treatment of UL spasticity with 8 U/kg BW NT 201 (maximum of 200 U) for:\n\n          1. At least one of the main clinical target patterns flexed elbow (4 U/kg BW) and/or\n             flexed wrist (2 U/kg BW).\n\n             and\n\n          2. Additional clinical patterns in the same limb (i.e., clenched fist, thumb in palm,\n             and/or pronated forearm) with the remaining units until maximum dose of 8 U/kg BW\n             (maximum of 200 U) for treatment of a single UL is reached.\n\n        plus\n\n        D2) Bilateral treatment of LL spasticity with 8 U/kg BW (maximum of 200 U). Dose must be\n        distributed into at least one of clinical target patterns pes equinus, flexed knee,\n        adducted thigh, and extended great toe, on each side. Dose distribution may vary between\n        sides as clinically needed.\n\n        E. Bilateral UL treatment and bilateral LL treatment (GMFCS I-III)\n\n        E1) Bilateral treatment of UL spasticity with equal doses of 8 U/kg BW NT 201 (maximum of\n        200 U) to each UL. Dose per UL must be distributed between\n\n          1. at least one of the main clinical target patterns flexed elbow (4 U/kg BW) and/or\n             flexed wrist (2 U/kg BW) and\n\n          2. additional clinical patterns in the same limb (i.e., clenched fist, thumb in palm,\n             and/or pronated forearm) with the remaining units until maximum dose of 8 U/kg BW\n             (maximum of 200 U) for treatment of a single UL is reached.\n\n        plus\n\n        E2) Bilateral treatment of LL spasticity with 4 U/kg BW (maximum of 100 U). Dose must be\n        distributed into at least one of clinical target patterns pes equinus, flexed knee,\n        adducted thigh, and extended great toe, on each side. Dose distribution may vary between\n        sides as clinically needed.\n\n        Exclusion Criteria:\n\n        Pre-treated (non-na\u00efve) subjects must not have received BoNT treatment within the last 16\n        weeks prior to study treatment at V2 in any indication."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "344", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02002884", 
            "org_study_id": "MRZ60201_3072_1"
        }, 
        "intervention": [
            {
                "arm_group_label": "8 Units per kg body weight incobotulinumtoxinA (Xeomin)", 
                "description": "Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.", 
                "intervention_name": "IncobotulinumtoxinA (8 Units per kg body weight)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Xeomin", 
                    "NT 201", 
                    "Botulinum toxin type A (150 kiloDalton), free from complexing proteins"
                ]
            }, 
            {
                "arm_group_label": "6 Units per kg body weight incobotulinumtoxinA (Xeomin)", 
                "description": "Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% odium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.", 
                "intervention_name": "IncobotulinumtoxinA (6 Units per kg body weight)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Xeomin", 
                    "NT 201", 
                    "Botulinum toxin type A (150 kiloDalton), free from complexing proteins"
                ]
            }, 
            {
                "arm_group_label": "2 Units per kg body weight incobotulinumtoxinA (Xeomin)", 
                "description": "Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.", 
                "intervention_name": "IncobotulinumtoxinA (2 Units per kg body weight)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Xeomin", 
                    "NT 201", 
                    "Botulinum toxin type A (150 kiloDalton), free from complexing proteins"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Upper limb spasticity", 
            "lower limb spasticity", 
            "combined upper and lower limb spasticity"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Gulf Breeze", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32561"
                    }, 
                    "name": "Merz Investigational Site #001286"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wellington", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33414"
                    }, 
                    "name": "Merz Investgational Site #001284"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Savannah", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "31406"
                    }, 
                    "name": "Merz Investigational Site #001285"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Merz Investigational Site #001186"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbia", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "65212"
                    }, 
                    "name": "Merz Investigational Site #001283"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin\u00ae (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy", 
        "overall_contact": {
            "email": "clinicaltrials@merz.de", 
            "last_name": "Public Disclosure Manager"
        }, 
        "overall_official": {
            "affiliation": "Merz Pharmaceuticals GmbH", 
            "last_name": "Merz Medical Expert", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Canada: Health Canada", 
                "Mexico: Federal Commission for Protection Against Health Risks"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Primary clinical target pattern is defined by the investigator. The AS is a well known and commonly used scale in clinical trials with spasticity. In spastic muscles the resistance to passive movement is assessed. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).", 
                "measure": "Change from baseline in Ashworth Scale (AS) in the primary clinical target pattern, i.e. elbow flexors or wrist flexors", 
                "safety_issue": "No", 
                "time_frame": "Baseline to week 4"
            }, 
            {
                "description": "This is a co-primary outcome measure. The GICS is used to measure the investigator's impression of change due to treatment. The response option is a common 7-point Likert scale that ranges from -3 = very much worse to +3 = very much improved.", 
                "measure": "Investigator's Global Impression of Change Scale (GICS)", 
                "safety_issue": "No", 
                "time_frame": "Week 4"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02002884"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "This analysis will be performed in case two target patterns would qualify as main clinical target pattern for the main clinical target pattern not analyzed as primary efficacy variable.", 
                "measure": "Change from baseline in AS score of the other treated main clinical target pattern (i.e. of elbow flexors or wrist flexors, if treated)", 
                "safety_issue": "No", 
                "time_frame": "Week 4"
            }, 
            {
                "description": "In subjects treated in combination with flexed wrist.", 
                "measure": "Change from baseline in AS score of treated clinical target pattern clenched fist", 
                "safety_issue": "No", 
                "time_frame": "Week 4"
            }, 
            {
                "measure": "Change from baseline in AS score for each treated clinical pattern (e.g., flexed elbow, flexed wrist, clenched fist, etc.) of the upper limb at all other post baseline visits of main period", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to week 14"
            }, 
            {
                "description": "Assessed with 'Questionnaire on Pain caused by Spasticity (QPS)'.", 
                "measure": "Change from baseline in scores of pain intensity (from subjects) and pain frequency (from parent/caregiver) at all other post baseline visits of main period", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to week 14"
            }, 
            {
                "measure": "Child's/Adolescent's GICS (if applicable)", 
                "safety_issue": "No", 
                "time_frame": "Week 4"
            }, 
            {
                "measure": "Parent's/Caregiver's GICS", 
                "safety_issue": "No", 
                "time_frame": "Week 4"
            }
        ], 
        "source": "Merz Pharmaceuticals GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merz Pharmaceuticals GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}